Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations.
about
Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience.Touchscreen questionnaire patient data collection in rheumatology practice: development of a highly successful system using process redesign.Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection.Reliability and validity of the cross-culturally adapted French version of the Core Outcome Measures Index (COMI) in patients with low back painMeasures of rheumatoid arthritis disease activity in Australian clinical practiceUsefulness of patients-reported outcomes in rheumatoid arthritis focus group.PROMs in inflammatory arthritis: moving from static to dynamic.Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study.Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis.Anti-cyclic citrullinated peptide antibodies do not reflect self-reported disability and physical health in patients with rheumatoid arthritis of less than 5 years of duration.Variability in the frequency of rheumatology consultations in patients with rheumatoid arthritis in Spain.Morning stiffness and other patient-reported outcomes of rheumatoid arthritis in clinical practice.Rheumatoid arthritis: recommendations for treat to target.
P2860
Q30566220-C76D73C2-30E6-4385-8667-63BBF9D89485Q34097474-2032121C-5FB7-4DF0-9B4E-7D2DA18ED67CQ34409073-03AB5BE9-8637-451D-B584-F4D1E0C3F2B2Q35503257-1F5A6F59-7D62-4791-BB8A-11E23E0C6057Q35655960-8E5563BD-59E7-453E-815D-105AB016A67CQ35687818-5E06F0E5-14D4-40D6-858E-8F375602CE32Q36302285-970B7EED-84FC-48E9-B352-01EE163C493EQ38097709-623EB7E0-FD02-422A-916C-9CB29A73CD41Q38592344-75E1EB51-7F9D-4B8D-B579-F685D5C751F2Q39066165-CEA1F048-05E8-492B-AF5C-1A94F1F594DAQ43805423-F267BD18-5C27-4A10-B2EE-F8435006F3B0Q48105582-40AD7CFA-C2A4-497D-85AC-BA8153309609Q48304448-96E3499E-320D-480E-8A75-80321A16E3C5Q51098038-5F6029AE-79E9-43FC-B8C7-DB27FD287C7E
P2860
Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Quantitative measures of rheum ...... s, advantages and limitations.
@en
type
label
Quantitative measures of rheum ...... s, advantages and limitations.
@en
prefLabel
Quantitative measures of rheum ...... s, advantages and limitations.
@en
P1476
Quantitative measures of rheum ...... s, advantages and limitations.
@en
P2093
Tuulikki Sokka
Yusuf Yazici
P304
P356
10.1016/J.BERH.2007.02.007
P577
2007-08-01T00:00:00Z